Compositions and Methods for Inhibiting Expression of TGF-BETA Receptor Genes
3 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a TGF-beta receptor type I gene, comprising an antisense strand having a nucleotide sequence which is less than 30 nucleotides in length and which is substantially complementary to at least a part of a TGF-beta receptor type I gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a TGF-beta receptor type I gene using said pharmaceutical composition; and methods for inhibiting the expression of a TGF-beta receptor type I gene in a cell.
53 Citations
40 Claims
-
1-20. -20. (canceled)
- 21. A double-stranded ribonucleic acid molecule capable of inhibiting the expression of a human TGF-beta receptor type I gene in vitro by at least 80%.
-
25. A double-stranded ribonucleic acid molecule comprising a sense strand sequence selected from the group consisting of SEQ ID NOS:
- 1, 117, 103, 31, 81, 99, 23, 13, 29 and 7; and
an antisense strand sequence selected from the group consisting of SEQ ID NOS;
2, 118, 104, 32, 82, 100, 24, 14, 30 and 8. - View Dependent Claims (26, 27, 28, 29, 30, 37, 39)
- 1, 117, 103, 31, 81, 99, 23, 13, 29 and 7; and
-
31. A double-stranded ribonucleic acid molecule comprising a sense strand sequence selected from the group consisting of SEQ ID NOS:
- 151, 249, 261, 231, 275, 253, 211, 265, 181, 185, 209, 299, 295, 279 and 219; and
an antisense strand sequence selected from the group consisting of SEQ ID NOS;
152, 250, 262, 232, 276, 254, 212, 266, 182, 186, 210, 300, 296, 280 and 220. - View Dependent Claims (32, 33, 34, 35, 36, 38, 40)
- 151, 249, 261, 231, 275, 253, 211, 265, 181, 185, 209, 299, 295, 279 and 219; and
Specification